A number of other equities analysts also recently issued reports on ETON. HC Wainwright reissued a buy rating and issued a $21.00 price objective (up previously from $18.00) on shares of Eton Pharmaceuticals in a report on Wednesday, October 23rd. Zacks Investment Research cut shares of Eton Pharmaceuticals from a hold rating to a sell rating in a report on Friday, November 22nd. Finally, B. Riley began coverage on shares of Eton Pharmaceuticals in a research report on Friday, September 20th. They issued a buy rating and a $13.50 price target on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $13.75.
ETON stock opened at $5.97 on Wednesday. The business’s 50-day moving average is $6.02 and its two-hundred day moving average is $6.59. Eton Pharmaceuticals has a fifty-two week low of $5.13 and a fifty-two week high of $10.20.
Large investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in Eton Pharmaceuticals by 181.2% in the 2nd quarter. BlackRock Inc. now owns 26,092 shares of the company’s stock worth $206,000 after purchasing an additional 16,813 shares during the period. Vanguard Group Inc. increased its position in Eton Pharmaceuticals by 6.7% in the second quarter. Vanguard Group Inc. now owns 28,762 shares of the company’s stock worth $227,000 after buying an additional 1,800 shares in the last quarter. First Allied Advisory Services Inc. bought a new position in shares of Eton Pharmaceuticals in the third quarter worth about $228,000. First Trust Advisors LP bought a new position in shares of Eton Pharmaceuticals in the third quarter worth about $155,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Eton Pharmaceuticals by 122.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,139 shares of the company’s stock worth $25,000 after buying an additional 1,728 shares during the period. Hedge funds and other institutional investors own 12.80% of the company’s stock.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
Featured Story: Dogs of the Dow
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.